The company is not selling any of its common stock pursuant to this prospectus, and will not receive any proceeds from the sale of its common stock offered by this prospectus by the selling stockholders.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRZN:
- Surrozen’s Strategic Shift to Ophthalmology and Wnt Pathway Innovations Justify Buy Rating
- Surrozen Focuses on Ophthalmology Amid Financial Challenges
- Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year
- Surrozen Secures $76.4M in Private Placement Deal
- Surrozen to focus Wnt expertise, technologies on ophthalmology programs
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue